4th RNA Editing Summit

The 4th RNA Editing Summit returns as the first and only industry-dedicated forum solely focused on the research and therapeutic potential of RNA editing.

Our 2023 event will welcome first disclosures of exciting data with important learnings being communicated so the field can advance toward the clinic. Expect exclusive data from KOLs on the most recent developments in ADAR, APOBEC, CRISPR-Cas13, Cas7-11, and exon editing. Join 80+ thought leaders from the likes of Wave Life Sciences, ProQR, Shape Therapeutics and Korro Bio to stay ahead of the curve and tap into the therapeutic potential of RNA editing and accelerate clinical validation.

Bringing together a new group of RNA editing senior decision makers, a brand new 6-hour workshop day will delve into the key challenges facing RNA editing, including delivery, manufacturing and proof-of-concept.

URLs:
Website: https://go.evvnt.com/1556332-0?pid=10018
Tickets: https://go.evvnt.com/1556332-2?pid=10018
Brochure: https://go.evvnt.com/1556332-3?pid=10018

Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

Prices:
Industry - Conference + Workshop Day: USD 5296.00,
Industry - Conference Only: USD 3199.00,
Vendor - Conference + Workshop Day: USD 6196.00,
Vendor - Conference Only: USD 3799.00,
Academic - Conference + Workshop Day: USD 4596.00,
Academic - Conference Only: USD 2799.00

Speakers: Brain Booth, Principal Scientist, Shape Therapeutics, Daniel Rosan, Chief Business and Financial Officer, Ascidian Therapeutics, Dave Mauger, Director of Data Science, Arrakis Therapeutics, David Guay, Vice President of Innovation, Feldan Therapeutics, Feng Damon Wang, Post Doc Associate, Jon Watts Lab (RNA Therapeutics Institute UMass Chan Medical School), Gerard Platenburg, Chief Scientific Officer and Co-Founder, ProQR, Gurumurthy Channabasavaiah, Professor Nebraska, Medical Center, Hagen Cramer, Chief Production Officer, QurAlis, Ian Harding, Scientist II, Wave Life Sciences, Jonathan Gootenberg, McGovern Fellow, MIT, Kunwoo Lee, Chief Executive Officer and Co-founder, GenEdit, Mateusz Maciejewski, Vice President, Head of Data Science, Korro Bio, Miriam Bujny, Chief Development Officer, Sapreme Technologies, Mohamed ElSayed, Executive Vice President and Chief Technology Officer, RVAC Medicines, Nagy Habib, Head of Research, MiNA Therapeutics, Naveen Krishnan, Senior Director of Venture Investment, Bayer, Omar Abudayyeh, McGovern Fellow, MIT, Paul Bolno, President and Chief Executive Officer, Wave Life Sciences, Prashant Monian, Senior Scientist, Wave Life Sciences, Raj Pandey, Vice President of Chemistry, Cargene, Ron Hause, Vice President and Head of Analytics and Informatics, Shape Therapeutics, Ron Weiss, Professor, MIT, Sandy Hinckley, Senior Director, Head of Discovery Biology, QurAlis, Steven Seedhouse, Managing Director, Biotechnology Equity Research, Raymond James, Thomas de Vlaam, Principal, VC Pillar, Venkata Krishnamurthy, Senior Vice President, Head of Platform, Korro Bio